Literature DB >> 16335883

Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension.

Joel M Neutel1, Thomas W Littlejohn, Steven G Chrysant, Ashish Singh.   

Abstract

Hypertension is risk factor for cardiovascular morbidity and mortality, and stroke. A critical surge in blood pressure occurs during the early morning hours coincident with increased incidences of myocardial infarction, unstable angina, stroke and sudden cardiac death. This suggests that, in patients with hypertension, it may be important to maintain the efficacy of antihypertensive medication over the 24-h dosing interval, especially in the risky early morning hours. In order to evaluate the antihypertensive efficacies of fixed-dose combinations of angiotensin II receptor blockers with hydrochlorothiazide (HCTZ) 12.5 mg, a multicenter, randomized, prospective, open-label, blinded-endpoint study was performed in 805 patients with mild-to-moderate hypertension randomized to once-daily treatment with telmisartan 40 mg plus HCTZ (T40/H12.5), losartan 50 mg plus HCTZ (L50/H12.5), or telmisartan 80 mg plus HCTZ (T80/H12.5), with the primary objective of comparing T40/H12.5 with L50/H12.5 and evaluating the additional response of T80/H12.5. Efficacy was assessed by ambulatory blood pressure monitoring (ABPM), clinic seated cuff sphygmomanometry and calculated responder rates after 6 weeks' active treatment. The primary endpoint was reduction from baseline in the last 6-h mean (relative to dosing) diastolic blood pressure (DBP) measured using 24-h ABPM. Compared with the L50/H12.5 group, the mean reductions in the last 6-h mean DBP for the T40/H12.5 and T80/H12.5 groups were significantly greater: -2.0 mmHg (p=0.0031) and -2.8 mmHg (p=0.0003), respectively. We conclude that T40/H12.5 provided clinically and statistically significantly superior blood pressure reductions compared with L50/H12.5 during the last 6 h of the 24-h dosing interval, which corresponds to the high-risk early-morning hours, and that T80/H12.5 provided additional blood pressure reductions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335883     DOI: 10.1291/hypres.28.555

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  17 in total

Review 1.  Telmisartan: a review of its use in the management of hypertension.

Authors:  Anna J Battershill; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Effect of placebo on ambulatory blood pressure monitoring in children.

Authors:  Karen Redwine; Lee Howard; Pippa Simpson; Shun-Hwa Li; Ke Yan; Laura James; Jeffrey Blumer; Janice Sullivan; Robert Ward; Thomas Wells
Journal:  Pediatr Nephrol       Date:  2012-05-24       Impact factor: 3.714

Review 3.  Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

4.  Temporal changes in expression of connexin 43 after load-induced hypertrophy in vitro.

Authors:  Tepmanas Bupha-Intr; Kaylan M Haizlip; Paul M L Janssen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-09       Impact factor: 4.733

Review 5.  Using fixed-dose combination therapies to achieve blood pressure goals.

Authors:  Steven G Chrysant
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 6.  Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.

Authors:  David H G Smith
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Efficacy and tolerability of a fixed-dose combination of metoprolol extended release/amlodipine in patients with mild-to-moderate hypertension: a randomized, parallel-group, multicentre comparison with losartan plus amlodipine.

Authors:  Anil Pareek; Nitin B Chandurkar; Ravishankar Sharma; Dharmendra Tiwari; Bhagwan S Gupta
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 8.  Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension.

Authors:  Greg L Plosker; William B White
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Comparative efficacy and safety of triple therapy (ramipril, telmisartan, hydrochlorothiazide) vs dual anti hypertensive therapy (ramipril or telmisartan, hydrochlorothiazide) in stage 2 hypertensive patients.

Authors:  Bharat Bhushan; Seema Gupta; Vijay Khajuria; Dinesh Kumar; Mohan Lal; Dharminder Kumar; Sanjeev Bhat; Aman Sharma
Journal:  J Clin Diagn Res       Date:  2014-08-20

Review 10.  Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.

Authors:  Luis M Ruilope
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.